A collaboration between researchers from Ipatimup/i3S, INEB/i3S and Universidade de Aveiro led to the development of a novel photoimmunoconjugate of porphyrin conjugated to trastuzumab that specifically and efficiently eliminates HER2+ gastric cancer cells following photodynamic therapy in vitro and in vivo (when compared to trastuzumab alone).
This study suggests that, in the setting of human disease, repetitive cycles of Trast:Porph photoimmunotherapy may improve treatment of HER2+ gastric cancer patients.
Authors and Affiliations:
